Qingdao Vland Biotech INC. Class A

Qingdao Vland Biotech INC. Class A

SSSE:603739
11.60
CNY
+0.10
(+0.87%)
0.39EPS
50.19P/E
3.55BMarket Cap
Apr 26Next Earn

Total Valuation

CNY

As of September 30, 2026, Qingdao Vland Biotech INC. Class A carries a market capitalization of 3.55B, placing it among publicly traded companies globally. Its enterprise value stands at 3.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.55B
Enterprise Value3.83B

Important Dates

Qingdao Vland Biotech INC. Class A's next confirmed earnings release is scheduled for April 26, 2027.

Earnings Date4/26/2027

Share Statistics

As of September 30, 2026, Qingdao Vland Biotech INC. Class A has 253.03M shares outstanding.

Shares Outstanding253.03M

Valuation Ratios

As of September 30, 2026, Qingdao Vland Biotech INC. Class A trades at a trailing price-to-earnings ratio of 50.19. The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 1.95.

PE Ratio50.19
PS Ratio2.46
PB Ratio1.95
P/TBV Ratio2.23

Enterprise Valuation

As of September 30, 2026, Qingdao Vland Biotech INC. Class A trades at an EV/EBITDA multiple of 32.55 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.83B versus a market cap of 3.55B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.65
EV / EBITDA32.55
EV / EBIT32.55

Financial Position

As of September 30, 2026, Qingdao Vland Biotech INC. Class A maintains a current ratio of 1.31, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.79, indicating elevated leverage, while an interest coverage ratio of 7.10 demonstrates adequate ability to service its debt obligations.

Current Ratio1.31
Quick Ratio0.47
Debt / Equity30.79
Debt / EBITDA5.07
Interest Coverage7.10

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Qingdao Vland Biotech INC. Class A posted a return on equity (ROE) of 3.99, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.39, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.24, useful for judging operating efficiency across full business cycles. The company generates approximately 950,790.49 in revenue per employee across its workforce of 1,522.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.61 indicates how many times Qingdao Vland Biotech INC. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.99
Return on Assets (ROA)2.39
Return on Invested Capital (ROIC)3.97
Return on Capital Employed (ROCE)2.24
Revenue Per Employee950,790.49
Employee Count1,522.00
Inventory Turnover3.61

Taxes

CNY

Over the twelve months ended September 30, 2026, Qingdao Vland Biotech INC. Class A recorded 17.13M in income tax expense. That works out to an effective tax rate of 14.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 116.75M, leaving 70.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax17.13M
Effective Tax Rate14.67

Stock Price Statistics

CNY

As of the close on November 17, 2026, Qingdao Vland Biotech INC. Class A's stock has declined approximately 27.82% over the past 52 weeks. The 50-day moving average sits at 12.44, while the 200-day moving average is 13.45.

52-Week Price Change-27.82%
50-Day Moving Average12.44
200-Day Moving Average13.45

Income Statement

CNY

Over the twelve months ended September 30, 2026, Qingdao Vland Biotech INC. Class A generated 1.45B in revenue and converted that into 70.94M in net income, yielding earnings per share of 0.39. EBITDA reached 117.72M, while operating income came in at 144.73M.

Revenue1.45B
Gross Profit635.52M
Operating Income144.73M
Pretax Income116.75M
Net Income70.94M
EBITDA117.72M
EBIT117.72M
Earnings Per Share (EPS)0.39

Balance Sheet

CNY

As of September 30, 2026, Qingdao Vland Biotech INC. Class A holds 438.45M in cash and equivalents against 597.32M in total debt, resulting in a net debt position of 433.72M. Total book value stands at 1.82B, with working capital of 285.63M providing operational flexibility.

Cash & Cash Equivalents438.45M
Total Debt597.32M
Net Debt433.72M
Equity (Book Value)1.82B
Book Value Per Share7.19
Working Capital285.63M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-75.54M

Margins

Over the twelve months ended September 30, 2026, Qingdao Vland Biotech INC. Class A posted a gross margin of 43.92, reflecting its pricing power and cost economics. The operating margin of 10.00 and net profit margin of 4.90 provide insight into operational efficiency.

Gross Margin43.92
Operating Margin10.00
Pretax Margin8.07
Profit Margin4.90
EBITDA Margin8.14

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Qingdao Vland Biotech INC. Class A paid dividends of 0.16 per share. The dividend payout ratio of 32.32 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Qingdao Vland Biotech INC. Class A shareholders.

Dividend Per Share0.16
Payout Ratio32.32
Shareholder Yield4.84

Stock Splits

Qingdao Vland Biotech INC. Class A's most recent stock split took place on May 25, 2021 with a 5:7 split ratio.

Last Split Date5/25/2021
Split Ratio5:7

Scores

As of September 30, 2026, Qingdao Vland Biotech INC. Class A has an Altman Z-Score of 3.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.27